Crossbeta header

Corporate Development

Crossbeta Biosciences is a spin-off company from the University of Utrecht and the Utrecht University Medical Center. After its foundation in 2005, Crossbeta Biosciences quickly increased it critical mass and has exponentially expanded its research capabilities. The company now focuses on transforming its core technologies into commercial products, such as vaccines and products for the treatment of diseases associated with the misfolding of proteins. A recent expansion of its share capital allowed Crossbeta Biosciences to quickly expand its scientific staff. We have recently moved to new office and state-of-the art lab facilities supporting the further and expedite development of our commercial product pipeline. We actively seek for strategic alliances with pharmaceutical and biotech parties for the discovery and development of vaccines and pharmaceuticals in the area of RA and cardiovascular disease.